By Michael Gwarisa
Dr. Nyaradzo Mgodi, a renowned Zimbabwean clinician-researcher and the Site Leader for the University of Zimbabwe Clinical Trials Research Centre (UZ-CTRC) in Zengeza, has been awarded the prestigious HIV Vaccine Trials Network (HVTN) Service Award for her outstanding leadership and contribution to the groundbreaking Antibody Mediated Prevention (AMP) study.
The award was announced during the recent HVTN Full Group Meeting, a global gathering of leading scientists and researchers involved in HIV vaccine development. The AMP study, one of the most ambitious HIV prevention trials ever undertaken, investigated whether broadly neutralizing antibodies (bNAbs) could safely and effectively prevent HIV infection — a question that had never been answered at this scale until now.
Dr. Mgodi’s recognition places Zimbabwe in the spotlight for its vital role in advancing global HIV prevention research. As the principal investigator for the Zengeza site and one of the protocol co-chairs of the global AMP study, Dr. Mgodi was instrumental in leading the implementation of the trial in Zimbabwe and contributing to its overall scientific direction.
In an exclusive interview with HealthTimes following the conferment of the award, Dr. Mgodi expressed humility and pride in being part of a global scientific breakthrough.
This award doesn’t belong to me; I just represent all the people that got this award,” she said. “AMP was a very unique study. It was a proof-of-concept study — the first ever in the history of medical research to prove that, yes, monoclonal antibodies can prevent HIV. It had never been done before, and this is the first time we did such a study. It was a huge study conducted across 46 clinics in four continents — Europe, North America, South America, and of course Africa, including Zimbabwe and many other countries.”
The AMP study evaluated the effectiveness of a monoclonal antibody known as VRC01, administered through intravenous infusion, in preventing HIV infection among at-risk populations. The trial marked a new era in HIV prevention research by testing a biomedical intervention that mimics the immune response typically generated by a vaccine.
Dr. Mgodi admitted that she initially had reservations about the scale and complexity of the study.
“As a Zimbabwean, at first I thought I had been set up for failure — this is going to be difficult,” she said. “But I said, you know what, we have good teams of researchers across the world, and we had a lot of community engagement. The regulatory framework in most countries was good, and we worked closely with stakeholders whom we consulted before, during, and after the study.”
She emphasized the collective effort that went into the success of the trial and the importance of meaningful community involvement in such research.
“Community engagement was key to our success. We couldn’t have done it without the participants and the communities who trusted us and believed in the science. This is as much their award as it is mine.”
The AMP study’s findings are expected to significantly inform future HIV vaccine development and prevention strategies, particularly in high-burden regions like sub-Saharan Africa, where young women and adolescent girls remain at high risk of acquiring HIV.
Dr. Mgodi also highlighted the importance of representation and visibility for African researchers in global scientific collaborations.
“I am really excited. It’s such an honour indeed to receive such a prestigious award,” she said. “I am happy, and I hope I have been a good ambassador for the University of Zimbabwe and for the country. Because as Zimbabwe, we were part of the leadership. I wasn’t just representing myself as Nyaradzo Mgodi or UZ — I carried the flag of the country wherever I went.”
Her recognition by the HVTN sends a strong message about the growing role of African scientists in shaping the future of medical research and leading complex clinical trials. It also affirms the capacity of institutions like UZ-CTRC to contribute meaningfully to global health solutions.
In a congratulatory statement, UZ-CTRC applauded Dr. Mgodi for bringing honour to the institution and to Zimbabwe.
“A big congratulations to Dr. Mgodi for this special recognition of her leadership,” read the statement. “Her work continues to inspire a generation of researchers in Zimbabwe and across Africa.”
Dr. Mgodi’s leadership in the AMP study and her international recognition also come at a time when Zimbabwe is scaling up efforts to adopt innovative, science-based solutions to combat HIV. With the country aiming to achieve epidemic control through prevention, testing, and treatment, her success story reinforces the importance of investment in local research and capacity-building.
The award is not only a personal milestone for Dr. Mgodi but a celebration of Zimbabwe’s growing footprint in global scientific research.
“This award motivates me to keep pushing boundaries in science and to support the next generation of researchers, especially women, who want to make a difference,” she added.
